Compare Marathon Digital Holdings Inc (MARA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Digital Holdings Inc vs Novartis AG — how do they compare? Marathon Digital Holdings Inc trades at $12.29 (market cap $4.45B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 65.2× Marathon Digital Holdings Inc's market cap, and Novartis AG pays a 3.17% dividend while Marathon Digital Holdings Inc pays none. Which is the better fit depends on your goals.
| MARA | NVS | |
|---|---|---|
Market Cap | $4.45B | $290.25B |
Sector | Technology | Health |
52-Week High | $22.84 | $168.62 |
52-Week Low | $6.73 | $113.50 |
Enterprise Value | $6.40B | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MARA trades at $11.67, up 9.17% in the last session, but remains in a bearish technical trend. The company reported a net loss of $1.31 billion in 2025 with a negative net margin of 234.83%, though it maintains a high gross margin of 79.22%. Recent news highlights a strategic pivot to AI data centers, including a major Texas land acquisition announced on July 9, 2026, which could add up to 2 GW of power capacity.
The outlook is mixed: analyst consensus is a buy with a $16.90 price target, but significant risks persist from ongoing losses and high volatility. The AI pivot offers growth potential, yet execution and funding challenges pose substantial downside risk for investors.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Digital Holdings Inc
Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.
Read more on MARA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
